Oral administration of WFA with a dose of 3–5 mg/kg inhibited the activation of Akt and facilitated the FOXO3a-(Forkhead box O3a) mediated activation of Par-4 (prostate apoptosis response-4) leading to delayed tumor progression in preclinical prostate cancer models. Here, AKT1 is linked to prostate carcinoma.